KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $4.64.

  • Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) rose 3144.48% to $4.64 in Q4 2025 from the same period last year, while for Dec 2025 it was $15.32, marking a year-over-year increase of 80599.08%. This contributed to the annual value of $15.32 for FY2025, which is 83653.85% up from last year.
  • Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to $4.64 in Q4 2025, which was up 3144.48% from $4.2 recorded in Q3 2025.
  • Vertex Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $4.64 during Q4 2025, with a 5-year trough of -$13.92 in Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around $2.44, with its median value being $3.4 (2021).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) soared by 110384.62% in 2022, and later plummeted by 49545.45% in 2024.
  • Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at $2.96 in 2021, then increased by 6.67% to $3.16 in 2022, then grew by 17.38% to $3.71 in 2023, then fell by 4.85% to $3.53 in 2024, then surged by 31.44% to $4.64 in 2025.
  • Its EPS (Weighted Average and Diluted) was $4.64 in Q4 2025, compared to $4.2 in Q3 2025 and $3.99 in Q2 2025.